BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38348665)

  • 1. Serum neurofilament light chain in hereditary transthyretin amyloidosis: validation in real-life practice.
    Carroll AS; Razvi Y; O'Donnell L; Veleva E; Heslegrave A; Zetterberg H; Vucic S; Kiernan MC; Rossor AM; Gillmore JD; Reilly MM
    Amyloid; 2024 Jun; 31(2):95-104. PubMed ID: 38348665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal analysis of serum neurofilament light chain levels as marker for neuronal damage in hereditary transthyretin amyloidosis.
    Berends M; Brunger AF; Bijzet J; Kroesen BJ; Drost G; Lange F; Teunissen CE; In 't Veld S; Vrancken AF; Gans ROB; Hazenberg BPC; van der Zwaag PA; Nienhuis HLA
    Amyloid; 2024 Jun; 31(2):132-141. PubMed ID: 38477065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum neurofilament light chain: a promising early diagnostic biomarker for hereditary transthyretin amyloidosis?
    Romano A; Primiano G; Antonini G; Ceccanti M; Fenu S; Forcina F; Gentile L; Inghilleri M; Leonardi L; Manganelli F; Obici L; Sabino A; Sciarrone MA; Tozza S; Vitali F; Luigetti M
    Eur J Neurol; 2024 Jan; 31(1):e16070. PubMed ID: 37724995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated Amyloidosis.
    Ticau S; Sridharan GV; Tsour S; Cantley WL; Chan A; Gilbert JA; Erbe D; Aldinc E; Reilly MM; Adams D; Polydefkis M; Fitzgerald K; Vaishnaw A; Nioi P
    Neurology; 2021 Jan; 96(3):e412-e422. PubMed ID: 33087494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis.
    Louwsma J; Brunger AF; Bijzet J; Kroesen BJ; Roeloffzen WWH; Bischof A; Kuhle J; Drost G; Lange F; Kuks JBM; Gans ROB; Hazenberg BPC; Nienhuis HLA
    Amyloid; 2021 Mar; 28(1):50-55. PubMed ID: 32883119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers of axonal damage to favor early diagnosis in variant transthyretin amyloidosis (A-ATTRv).
    González-Moreno J; Gragera-Martínez Á; Rodríguez A; Borrachero-Garro C; García-Garrido S; Barceló C; Manovel-Sánchez A; Ribot-Sansó MA; Ibargüen-González L; Gomila R; Muñoz-Beamud F; Losada-López I; Cisneros-Barroso E
    Sci Rep; 2024 Jan; 14(1):581. PubMed ID: 38182630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurofilament light chain as a disease severity biomarker in ATTRv: data from a single-centre experience.
    Luigetti M; Di Paolantonio A; Guglielmino V; Romano A; Rossi S; Sabino A; Servidei S; Sabatelli M; Primiano G
    Neurol Sci; 2022 Apr; 43(4):2845-2848. PubMed ID: 35094171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy.
    Maia LF; Maceski A; Conceição I; Obici L; Magalhães R; Cortese A; Leppert D; Merlini G; Kuhle J; Saraiva MJ
    Amyloid; 2020 Jun; 27(2):97-102. PubMed ID: 31906707
    [No Abstract]   [Full Text] [Related]  

  • 9. Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study.
    van der Ende EL; Meeter LH; Poos JM; Panman JL; Jiskoot LC; Dopper EGP; Papma JM; de Jong FJ; Verberk IMW; Teunissen C; Rizopoulos D; Heller C; Convery RS; Moore KM; Bocchetta M; Neason M; Cash DM; Borroni B; Galimberti D; Sanchez-Valle R; Laforce R; Moreno F; Synofzik M; Graff C; Masellis M; Carmela Tartaglia M; Rowe JB; Vandenberghe R; Finger E; Tagliavini F; de Mendonça A; Santana I; Butler C; Ducharme S; Gerhard A; Danek A; Levin J; Otto M; Frisoni GB; Cappa S; Pijnenburg YAL; Rohrer JD; van Swieten JC;
    Lancet Neurol; 2019 Dec; 18(12):1103-1111. PubMed ID: 31701893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurological affection and serum neurofilament light chain in wild type transthyretin amyloidosis.
    Pernice HF; Knorz AL; Wetzel PJ; Herrmann C; Muratovic H; Rieber F; Asaad E; Fiß G; Barzen G; Blüthner E; Knebel F; Spethmann S; Messroghli D; Heidecker B; Brand A; Wetz C; Tschöpe C; Hahn K
    Sci Rep; 2024 May; 14(1):10111. PubMed ID: 38698025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration.
    Rojas JC; Wang P; Staffaroni AM; Heller C; Cobigo Y; Wolf A; Goh SM; Ljubenkov PA; Heuer HW; Fong JC; Taylor JB; Veras E; Song L; Jeromin A; Hanlon D; Yu L; Khinikar A; Sivasankaran R; Kieloch A; Valentin MA; Karydas AM; Mitic LL; Pearlman R; Kornak J; Kramer JH; Miller BL; Kantarci K; Knopman DS; Graff-Radford N; Petrucelli L; Rademakers R; Irwin DJ; Grossman M; Ramos EM; Coppola G; Mendez MF; Bordelon Y; Dickerson BC; Ghoshal N; Huey ED; Mackenzie IR; Appleby BS; Domoto-Reilly K; Hsiung GR; Toga AW; Weintraub S; Kaufer DI; Kerwin D; Litvan I; Onyike CU; Pantelyat A; Roberson ED; Tartaglia MC; Foroud T; Chen W; Czerkowicz J; Graham DL; van Swieten JC; Borroni B; Sanchez-Valle R; Moreno F; Laforce R; Graff C; Synofzik M; Galimberti D; Rowe JB; Masellis M; Finger E; Vandenberghe R; de Mendonça A; Tagliavini F; Santana I; Ducharme S; Butler CR; Gerhard A; Levin J; Danek A; Otto M; Sorbi S; Cash DM; Convery RS; Bocchetta M; Foiani M; Greaves CV; Peakman G; Russell L; Swift I; Todd E; Rohrer JD; Boeve BF; Rosen HJ; Boxer AL;
    Neurology; 2021 May; 96(18):e2296-e2312. PubMed ID: 33827960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral Blood Cell Gene Expression Diagnostic for Identifying Symptomatic Transthyretin Amyloidosis Patients: Male and Female Specific Signatures.
    Kurian SM; Novais M; Whisenant T; Gelbart T; Buxbaum JN; Kelly JW; Coelho T; Salomon DR
    Theranostics; 2016; 6(11):1792-809. PubMed ID: 27570551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum neurofilament light chain as a reliable biomarker of hereditary transthyretin-related amyloidosis-A Swiss reference center experience.
    Loser V; Benkert P; Vicino A; Lim Dubois Ferriere P; Kuntzer T; Pasquier J; Maceski A; Kuhle J; Theaudin M
    J Peripher Nerv Syst; 2023 Mar; 28(1):86-97. PubMed ID: 36471582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A natural history analysis of asymptomatic
    Coelho T; Conceição I; Waddington-Cruz M; Keohane D; Sultan MB; Chapman D; Amass L;
    Amyloid; 2022 Dec; 29(4):228-236. PubMed ID: 35730447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual-Echo Turbo Spin Echo and 12-Echo Multi Spin Echo Sequences as Equivalent Techniques for Obtaining T2-Relaxometry Data: Application in Symptomatic and Asymptomatic Hereditary Transthyretin Amyloidosis as a Surrogate Disease.
    Poncelet A; Weiler M; Hegenbart U; Sam G; Schönland S; Purrucker JC; Hayes JM; Hund E; Bendszus M; Heiland S; Kollmer J
    Invest Radiol; 2022 May; 57(5):301-307. PubMed ID: 34839307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurofilament Light Chains in Systemic Amyloidosis: A Systematic Review.
    Berends M; Nienhuis HLA; Adams D; Karam C; Luigetti M; Polydefkis M; Reilly MM; Sekijima Y; Hazenberg BPC
    Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skin amyloid deposits and nerve fiber loss as markers of neuropathy onset and progression in hereditary transthyretin amyloidosis.
    Leonardi L; Adam C; Beaudonnet G; Beauvais D; Cauquil C; Not A; Morassi O; Benmalek A; Trassard O; Echaniz-Laguna A; Adams D; Labeyrie C
    Eur J Neurol; 2022 May; 29(5):1477-1487. PubMed ID: 35100482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy.
    Rasing I; Voigt S; Koemans EA; de Kort AM; van Harten TW; van Etten ES; van Zwet EW; Stoops E; Francois C; Kuiperij BH; Klijn CJM; Schreuder FHBM; van der Weerd L; van Osch MJP; van Walderveen MAA; Verbeek MM; Terwindt GM; Wermer MJH
    Alzheimers Res Ther; 2024 Apr; 16(1):86. PubMed ID: 38654326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corneal confocal microscopy identifies corneal nerve loss and increased Langerhans cells in presymptomatic carriers and patients with hereditary transthyretin amyloidosis.
    Thimm A; Carpinteiro A; Oubari S; Papathanasiou M; Kessler L; Rischpler C; Malik RA; Herrmann K; Reinhardt HC; Rassaf T; Kleinschnitz C; Hagenacker T; Stettner M
    J Neurol; 2023 Jul; 270(7):3483-3491. PubMed ID: 37014422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study.
    Ticau S; Aldinc E; Polydefkis M; Adams D; Coelho T; Ueda M; Hale C; Vest J; Nioi P;
    Amyloid; 2024 Mar; 31(1):1-11. PubMed ID: 37469249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.